Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

• Giulio Metro,
• Eleonora Gariazzo,
• Silvia Costabile,
• Sara Baglivo,
• Fausto Roila,
• Francesca Colamartini,
• Barbara Palumbo,
• Pietro Chiarini,
• Stefania Gori,
• Antonio Conti,
• Luca Marcomigni,
• Guido Bellezza,
• Gianluigi Lunardi

Affiliations

Giulio Metro

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Eleonora Gariazzo

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Silvia Costabile

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Sara Baglivo

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Fausto Roila

Medical Oncology, Department of Medicine and Surgery, University of Perugia

Francesca Colamartini

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Barbara Palumbo

Department of Medicine and Surgery, Section of Nuclear Medicine and Health Physics, University of Perugia

Pietro Chiarini

Neuroradiology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Stefania Gori

Medical Oncology, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella

Antonio Conti

Clinical Analysis Laboratory and Transfusional Medicine, Clinical Pharmacology, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella

Luca Marcomigni

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia

Guido Bellezza

Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, University of Perugia

Gianluigi Lunardi

Clinical Analysis Laboratory and Transfusional Medicine, Clinical Pharmacology, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella